Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis.

[1]  J. Hirsh,et al.  Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1992, Chest.

[2]  R. Vanholder,et al.  Adequacy of dialysis: a critical analysis. , 1992, Kidney international.

[3]  J. Hirsh,et al.  Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. , 1992, Blood.

[4]  M. D. Freedman,et al.  Pharmacodynamics, Clinical Indications, and Adverse Effects of Heparin , 1992, Journal of clinical pharmacology.

[5]  F. Markwardt,et al.  Pharmacology of r-hirudin in renal impairment. , 1992, Thrombosis research.

[6]  G. Raskob,et al.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. , 1992, The New England journal of medicine.

[7]  M. Hropot,et al.  Interference of heparin and analogues with hirudin in the chromogenic thrombin substrate assay. , 1991, Thrombosis research.

[8]  F. Markwardt.  Hirudin and Derivatives as Anticoagulant Agents , 1991, Thrombosis and Haemostasis.

[9]  F. Markwardt,et al.  Hirudin in haemodialysis. , 1990, Thrombosis research.

[10]  P. Badenhorst,et al.  The pharmacology of recombinant hirudin, a new anticoagulant. , 1990, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[11]  R. Huber,et al.  The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.

[12]  M. Levine,et al.  15 Side-effects of antithrombotic therapy , 1990 .

[13]  J. Soria,et al.  Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. , 1989, Blood.

[14]  W J Penny,et al.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. , 1989, Circulation.

[15]  C. Francis,et al.  Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers. , 1989, Circulation.

[16]  N. Hoenich,et al.  Morbidity and mortality of central venous catheter hemodialysis: a review of 10 years' experience. , 1987, Nephron.

[17]  G. Stöffler,et al.  Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin. , 1986, JIM - Journal of Immunological Methods.

[18]  F. Markwardt,et al.  Assay of hirudin in plasma using a chromogenic thrombin substrate. , 1985, Thrombosis research.

[19]  J. Hirsh,et al.  Bleeding associated with antithrombotic therapy. , 1980, Seminars in hematology.

[20]  J. Wilson,et al.  Variation among commercial activated partial thromboplastin time reagents in response to heparin. , 1977, American journal of clinical pathology.

[21]  J. Hirsh.  Drug therapy : heparin , 1991 .